Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1994 Sep;38(9):2172–2174. doi: 10.1128/aac.38.9.2172

Pure nucleoside enantiomers of beta-2',3'-dideoxycytidine analogs are selective inhibitors of hepatitis B virus in vitro.

R F Schinazi 1, G Gosselin 1, A Faraj 1, B E Korba 1, D C Liotta 1, C K Chu 1, C Mathé 1, J L Imbach 1, J P Sommadossi 1
PMCID: PMC284704  PMID: 7811039

Abstract

(-)-beta-L-2',3'-Dideoxycytidine (beta-L-DDC), (+)-beta-D-2',3'-dideoxycytidine (beta-D-DDC), (-)-beta-L-2',3'-dideoxy-5-fluorocytidine (beta-L-FDDC), (-)-beta-L-2',3'-dideoxy-5-fluoro-3'-thiacytidine (beta-L-FTC), and (+)-beta-D-1,3-dioxolane-5-fluorocytidine (beta-D-FDOC) were evaluated for their anti-hepatitis B virus (anti-HBV) activities in HBV-transfected human liver cells (2.2.15). The order of decreasing potency for the compounds at the 90% effect level was beta-D-FDOC > beta-L-FTC > beta-L-FDDC approximately beta-L-DDC >> beta-D-DDC. Inhibition of HBV in transfected liver cells by the cytosine nucleosides was selective. The beta-L-nucleoside-5'-triphosphates were consistently more potent inhibitors of woodchuck hepatitis virus DNA polymerase than the corresponding natural beta-D-enantiomers.

Full text

PDF
2173

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Furman P. A., Davis M., Liotta D. C., Paff M., Frick L. W., Nelson D. J., Dornsife R. E., Wurster J. A., Wilson L. J., Fyfe J. A. The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Antimicrob Agents Chemother. 1992 Dec;36(12):2686–2692. doi: 10.1128/aac.36.12.2686. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Gilson R. J., Hawkins A. E., Kelly G. K., Gill S. K., Weller I. V. No effect of zidovudine on hepatitis B virus replication in homosexual men with symptomatic HIV-1 infection. AIDS. 1991 Feb;5(2):217–220. doi: 10.1097/00002030-199102000-00014. [DOI] [PubMed] [Google Scholar]
  3. Gosselin G., Mathé C., Bergogne M. C., Aubertin A. M., Kirn A., Schinazi R. F., Sommadossi J. P., Imbach J. L. Enantiomeric 2',3'-dideoxycytidine derivatives are potent human immunodeficiency virus inhibitors in cell cultures. C R Acad Sci III. 1994 Jan;317(1):85–89. [PubMed] [Google Scholar]
  4. Gosselin G., Schinazi R. F., Sommadossi J. P., Mathé C., Bergogne M. C., Aubertin A. M., Kirn A., Imbach J. L. Anti-human immunodeficiency virus activities of the beta-L enantiomer of 2',3'-dideoxycytidine and its 5-fluoro derivative in vitro. Antimicrob Agents Chemother. 1994 Jun;38(6):1292–1297. doi: 10.1128/aac.38.6.1292. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Kim H. O., Schinazi R. F., Shanmuganathan K., Jeong L. S., Beach J. W., Nampalli S., Cannon D. L., Chu C. K. L-beta-(2S,4S)- and L-alpha-(2S,4R)-dioxolanyl nucleosides as potential anti-HIV agents: asymmetric synthesis and structure-activity relationships. J Med Chem. 1993 Mar 5;36(5):519–528. doi: 10.1021/jm00057a001. [DOI] [PubMed] [Google Scholar]
  6. Korba B. E., Gerin J. L. Use of a standardized cell culture assay to assess activities of nucleoside analogs against hepatitis B virus replication. Antiviral Res. 1992 Jul 1;19(1):55–70. doi: 10.1016/0166-3542(92)90056-b. [DOI] [PubMed] [Google Scholar]
  7. Lin T. S., Luo M. Z., Liu M. C., Pai S. B., Dutschman G. E., Cheng Y. C. Antiviral activity of 2',3'-dideoxy-beta-L-5-fluorocytidine (beta-L-FddC) and 2',3'-dideoxy-beta-L-cytidine (beta-L-ddC) against hepatitis B virus and human immunodeficiency virus type 1 in vitro. Biochem Pharmacol. 1994 Jan 20;47(2):171–174. doi: 10.1016/0006-2952(94)90002-7. [DOI] [PubMed] [Google Scholar]
  8. Maddrey W. C. Chronic viral hepatitis: diagnosis and management. Hosp Pract (Off Ed) 1994 Feb 15;29(2):117-20, 123-6, 129-32. doi: 10.1080/21548331.1994.11442979. [DOI] [PubMed] [Google Scholar]
  9. Schinazi R. F., Lloyd R. M., Jr, Nguyen M. H., Cannon D. L., McMillan A., Ilksoy N., Chu C. K., Liotta D. C., Bazmi H. Z., Mellors J. W. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob Agents Chemother. 1993 Apr;37(4):875–881. doi: 10.1128/aac.37.4.875. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Schinazi R. F., McMillan A., Cannon D., Mathis R., Lloyd R. M., Peck A., Sommadossi J. P., St Clair M., Wilson J., Furman P. A. Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Antimicrob Agents Chemother. 1992 Nov;36(11):2423–2431. doi: 10.1128/aac.36.11.2423. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Shewach D. S., Liotta D. C., Schinazi R. F. Affinity of the antiviral enantiomers of oxathiolane cytosine nucleosides for human 2'-deoxycytidine kinase. Biochem Pharmacol. 1993 Apr 6;45(7):1540–1543. doi: 10.1016/0006-2952(93)90058-5. [DOI] [PubMed] [Google Scholar]
  12. Van Draanen N. A., Tisdale M., Parry N. R., Jansen R., Dornsife R. E., Tuttle J. V., Averett D. R., Koszalka G. W. Influence of stereochemistry on antiviral activities and resistance profiles of dideoxycytidine nucleosides. Antimicrob Agents Chemother. 1994 Apr;38(4):868–871. doi: 10.1128/aac.38.4.868. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES